Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L GREENBERG

Showing results (861-870 of 881) with videos related to

Pageof 89
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Nature Metabolism|November 23, 2023
Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndromeValerian E Kagan, Yulia Y Tyurina, Karolina Mikulska-Ruminska, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Cell|March 20, 2012
Personal omics profiling reveals dynamic molecular and medical phenotypesRui Chen, George I Mias, Jennifer Li-Pook-Than, et al.
Blood|January 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerabilityMichal Sekrecki, Agata Sekrecka, Rohan R Lattupally, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Pageof 89

Showing results (861-870 of 881) with videos related to

Sort By:
Pageof 89
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Nature Metabolism|November 23, 2023
Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndromeValerian E Kagan, Yulia Y Tyurina, Karolina Mikulska-Ruminska, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Cell|March 20, 2012
Personal omics profiling reveals dynamic molecular and medical phenotypesRui Chen, George I Mias, Jennifer Li-Pook-Than, et al.
Blood|January 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerabilityMichal Sekrecki, Agata Sekrecka, Rohan R Lattupally, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Pageof 89